...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith-Oncology Pipeline
6
Mar 16, 2021 08:18AM
9
Mar 18, 2021 03:12PM
6
Mar 18, 2021 04:01PM
3
Mar 18, 2021 05:10PM
6
Mar 18, 2021 06:27PM
2
Mar 19, 2021 06:49AM
4
Mar 19, 2021 11:19AM
5
Mar 19, 2021 11:23AM
6
Mar 19, 2021 11:57AM
2
Mar 22, 2021 04:08PM
3
Mar 22, 2021 05:34PM

RVXOT, seeing that (OTCMKTS: RVXCF) trades on the OTC market and posted on the RVX page to the right-hand column, of the Resverlogix hub, why can't Agoracom similarly post the SPP for ZHCLF (Zenith)?

According to the MD&A, as of December 21, 2020, the number of Common Shares outstanding = 135,020,827.

At a US $0.40 closing SPP,  the market cap for Zenith is US $54 Mil +.

 

Koo

5
Mar 23, 2021 07:54AM
4
Mar 23, 2021 09:16AM
8
Mar 23, 2021 01:45PM
4
Mar 23, 2021 02:24PM
2
Mar 23, 2021 03:27PM
2
Mar 23, 2021 04:33PM
Share
New Message
Please login to post a reply